FOR IMMEDIATE RELEASE
Contact: John Richardson, CEO, CIMNET Inc.
(610) 790-1800 x1807, johnr@CimnetInc.com

CIMNET Receives Multi-Site MES Order in Life Sciences

Robesonia, PA, February 4, 2003

CIMNET®, Inc. (OTC BB: CIMK) a leading developer of manufacturing execution software today announced that their Factelligence™ Manufacturing Execution System (MES) has been selected for a multi-site installation by a global Life Sciences company. The goals of the implementations include integration to an existing ERP system, improving packaging line and production performance, lot genealogy, batch recipe management and 21 CFR Part 11 compliance.

Factelligence is a web-based MES designed to assist pharmaceutical and medical device manufacturers with 21CFR Part 11 regulatory compliance and productivity improvements. Factelligence builds an environment where recipe formulae, specifications, instructions, batch records and material traceability are electronically managed. Full real-time visibility for decision makers and supply chain management is created using the configurable tools in Factelligence and its XML capabilities.

"This is an important win for CIMNET because the rigorous evaluation of many MES packages conducted by this large manufacturer confirms the quality of the Factelligence software," stated Jason Dietrich, VP of CIMNET. "Our dedication to the pharmaceutical and life sciences space has been validated and our willingness to work closely with our customers is proving a positive benefit to the market."

About CIMNET: CIMNET designs, markets and integrates software for manufacturing facilities. CIMNET's products allow manufacturing companies to schedule and monitor work flow in real-time and reduce operating costs by improving the quality of products being produced. CIMNET's proprietary products, Factelligence and DNC Professional, are used by discrete and process manufacturers in the aerospace, automotive, pharmaceutical, medical devices, food and beverage and consumer packaged goods industries.

This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. When used in this release, the words "believe," "anticipate," "think," "intend," "plan," "will be," "expect," and similar expressions identify such forward-looking statements. Such statements regarding future events and/or the future financial performance of the Company are subject to certain risks and uncertainties which could cause actual events or the actual future results of the Company to differ materially from any forward-looking statement. Such risks and uncertainties include, among other things, the availability of any needed financing, the Company's ability to implement its business plan for various applications of its technologies, the impact of competition, the management of growth, and the other risks and uncertainties that may be detailed from time to time in the Company's reports or registration statements filed with The Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such statements should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.